United StatesHealth

Dr. Reddy’s (NYSE:RDY) announced the United States launch of Sugammadex Injection, a generic equivalent of Bridion, to expand its hospital portfolio.

Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 revenue of $219.1 million, up 32%, and announced an all-stock merger with Indivior Pharmaceuticals (NASDAQ:INDV).

CVS Health (NYSE:CVS) announced that its board of directors approved a quarterly cash dividend of $0.665 per share on its common stock, with payment scheduled for August 3, 2026.

ClearOne (NASDAQ:CLRO) said it has entered into a definitive merger agreement involving MergerSub, Vivani Medical (NASDAQ:VANI), and Cortigent, under which Cortigent will become a wholly owned subsidiary of ClearOne.

MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.

Incyte (NASDAQ:INCY) received Japanese regulatory approval for its cancer drug Minjuvi after clinical trials demonstrated response rates up to 71.4%.

Aurora Cannabis (NASDAQ:ACB) reported record global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, capitalizing on its structural pivot toward high-margin prescription markets in Europe and Australia.

Camurus (NASDAQ:CAMX) announced Monday that Eli Lilly (NYSE:LLY) has formally exercised its option to integrate amylin receptor agonists into the companies' existing cardiometabolic collaboration and license agreement.

Cosmos Health (NASDAQ:COSM) generated record revenue in the first quarter of 2026, driven by sustained distribution gains and market expansions, even as a shifting business mix and operational investments weighed on bottom-line profitability.

CorVel (NASDAQ:CRDL) reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, delivering top-line expansion and a double-digit increase in earnings per share as investments in artificial intelligence and automation optimized clinical workflows.

Lifeway Foods (NASDAQ:LWAY) reported a surge in first-quarter revenue that far outpaced analyst estimates, extending a multi-year growth streak fueled by the mainstreaming of gut-health products.

DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.